NASDAQ:CDT Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free CDT Stock Alerts $1.80 -0.22 (-10.89%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.64▼$2.0250-Day Range$1.80▼$3.3452-Week Range$0.95▼$25.00Volume109,646 shsAverage Volume61,081 shsMarket Capitalization$132.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Conduit Pharmaceuticals alerts: Email Address Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About Conduit Pharmaceuticals Stock (NASDAQ:CDT)Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Read More CDT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDT Stock News HeadlinesMay 22, 2024 | businesswire.comAstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024May 15, 2024 | investorplace.comCDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q1 2024March 19, 2024 | finance.yahoo.comConduit Pharmaceuticals Adds Key Leadership PositionsMarch 19, 2024 | globenewswire.comConduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific OfficerMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Opens New Laboratory in UKMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences HubMarch 11, 2024 | globenewswire.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences HubFebruary 28, 2024 | seekingalpha.comConduit Pharmaceuticals: Stellar Management Team, New Business ModelFebruary 15, 2024 | sg.finance.yahoo.comConduit Pharmaceuticals Inc. (CDT)February 13, 2024 | uk.finance.yahoo.comConduit Pharmaceuticals Inc. (CDTTW)January 31, 2024 | finance.yahoo.comConduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDecember 6, 2023 | wsj.comConduit Pharmaceuticals Inc.November 2, 2023 | finance.yahoo.comConduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare ConferenceOctober 31, 2023 | msn.comKXIN and ICU among pre-market losersOctober 28, 2023 | seekingalpha.comCDT Conduit Pharmaceuticals Inc.October 24, 2023 | uk.investing.comConduit Pharmaceuticals Inc (CDT)October 11, 2023 | finance.yahoo.comConduit Pharma CEO Tapolczay on Biopharma Differentiation, PipelineOctober 11, 2023 | finance.yahoo.comConduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656See More Headlines Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/15/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CUSIPN/A CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-20.19% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-180.00Miscellaneous Outstanding Shares73,830,000Free Float56,487,000Market Cap$132.89 million OptionableNot Optionable Beta2.46 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. David Joszef Tapolczay (Age 65)CEO & Director Comp: $419.8kMr. Adam Sragovicz (Age 54)Chief Financial Officer Comp: $116.67kDr. Joanne M. Holland (Age 49)Chief Scientific Officer Key CompetitorsPureTech HealthNASDAQ:PRTCStoke TherapeuticsNASDAQ:STOKOcular TherapeutixNASDAQ:OCULAurinia PharmaceuticalsNASDAQ:AUPHTango TherapeuticsNASDAQ:TNGXView All Competitors CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed in 2024? Conduit Pharmaceuticals' stock was trading at $4.55 on January 1st, 2024. Since then, CDT shares have decreased by 60.4% and is now trading at $1.80. View the best growth stocks for 2024 here. When is Conduit Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CDT earnings forecast. How were Conduit Pharmaceuticals' earnings last quarter? Conduit Pharmaceuticals Inc. (NASDAQ:CDT) posted its earnings results on Tuesday, May, 14th. The company reported ($0.05) EPS for the quarter. How do I buy shares of Conduit Pharmaceuticals? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDT) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredDouble-Threat Biotech Could Deliver Triple-Digit GainsMost investors haven't heard of this under-the-radar biotech... But it could emerge as one of the premier A...Behind the Markets | SponsoredA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.